A CD25-biased interleukin-2 for autoimmune therapy engineered via a semi-synthetic organism
Jerod L. Ptacin(Sanofi (Turkey)), Marcos E. Milla(Johnson & Johnson (United States))
Cited by 5
Related Papers
An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism
|Nature Communications|2021|117